Senores Pharmaceuticals Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹372 - ₹391
- Lot size
- 38 shares
- Issue amount
- ₹582.11 cr
- Total subscription
- 97.25×
- Opens
- 20 Dec 2024
- Closes
- 24 Dec 2024
- Allotment
- 26 Dec 2024
- Listing
- 30 Dec 2024
Offer at a glance
Issue overview
- Issue size
- 1,48,87,723 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹14,136
- Fresh issue
- ₹500 cr
- Offer for sale
- ₹82.11 cr
- Registrar
- Link Intime India Private Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,858
- Issue type
- Bookbuilding IPO
- Shares before issue
- 3,32,65,865
- Shares after issue
- 4,60,53,588
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail | 1 | 38 | ₹14,858 |
| sHNI | 14 | 532 | ₹2,08,012 |
| bHNI | 68 | 2,584 | ₹10,10,344 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| HNIs (10L+) | 2,644 | 53,198 |
| HNIs(2-10L) | 1,322 | 1,42,233 |
| Retail | 38,982 | 30,76,031 |
| Employee | 0 | 29,405 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| NIB | 86.88 | 8,734.89 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Sep-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| EPS | 7.2 | 13.67 | 8.87 |
| ROE | 8.69 | 23.6 | 20.55 |
| ROCE | 7.59 | 11.73 | 18.56 |
| RONW | 8.69 | 23.6 | 20.55 |
| PRE IPO | 0 | 39.77 | 0 |
| POST IPO | 28.21 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Senores Pharmaceuticals Limited, incorporated on December 26, 2017, is an Ahmedabad-based pharmaceutical company focused on developing, manufacturing, and marketing high-quality branded generic medicines for both domestic and global markets. Its diversified product portfolio spans key therapeutic areas, including gastrointestinal, cardiovascular, respiratory, pain management, and anti-infective segments. Driven by strong R&D capabilities, the company emphasizes innovation, cost-effective product development, and strict regulatory compliance. Senores operates through a robust distribution network supported by subsidiaries such as Ratnatris Pharmaceuticals Private Limited and Havix Group, Inc. (Aavis Pharmaceuticals). It serves customers across major international markets, including the US, Europe, and other emerging regions.
Strengths
- Global Market Presence: Strong footprint across regulated and semi-regulated markets ensures diversified revenue and reduced geographical dependence.
- Robust R&D & Manufacturing: Advanced R&D capabilities enable development of complex generics while adhering to strict global regulatory standards for quality.
- Strategic Partnerships: Long-term relationships with major clients, suppliers, and distributors support steady growth and consistent revenue visibility.
Risk factors
- Regulatory Challenges: Delays or denials in product approvals may hinder new launches and limit growth in key markets.
- Raw Material Volatility: Dependence on external API and raw material suppliers exposes the company to price fluctuations and supply disruptions.
- Intense Competition: A highly competitive pharma landscape may pressure pricing and reduce profit margins.
Promoters
Swapnil Jatinbhai Shah
Ashokkumar Vijaysinh Barot
Registrar & documents
Lead manager
Equirus Capital Private Limited, Ambit Private Limited, Nuvama Wealth Management Limited
Registrar & contacts
Link Intime India Private Limited
[email protected]Official registrar portal ↗Check allotment status on registrar →Registered office
1101 to 1103, 11th floor,, South Tower, ONE 42 oppositeJayantilal Park, Ambali Bopal Road, Ahmedabad,-380054
+91-79-29999857
[email protected]Company website ↗Frequently Asked Questions
What is Senores Pharmaceuticals IPO GMP today?
As of today, Senores Pharmaceuticals IPO Grey Market Premium (GMP) is reported at +₹284 per share. Based on the upper price band of ₹391, the estimated listing price is ₹675 (+72.6% expected listing gain). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.
What is the lot size and minimum investment for Senores Pharmaceuticals IPO?
The minimum bid lot size for Senores Pharmaceuticals IPO is 38 shares. At the cut-off price of ₹391 per share, retail investors need a minimum application amount of ₹14,858 per lot. Retail applicants can apply for a maximum of 13 lots (up to ₹2,00,000).
When will Senores Pharmaceuticals IPO allotment status be announced?
The allotment status for Senores Pharmaceuticals IPO is scheduled to be finalized on 26 Dec 2024. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Link Intime India Private Limited's official portal or via BSE/NSE allotment portals.
How can I check Senores Pharmaceuticals IPO allotment status online by PAN?
To check Senores Pharmaceuticals IPO allotment status: 1) Visit the registrar portal (Link Intime India Private Limited) or the BSE IPO allotment page. 2) Select 'Senores Pharmaceuticals Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.
Explore More IPO Analysis & Live Tools
Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.